Sistemic closes Series A; Keryx, FDA agree on late-stage study design

 @FierceBiotech:  Bioheart launches first FDA approved trial of gene-modified stem cell therapy in congestive heart failure. Release | Follow @FierceBiotech

 @JohnCFierce: You have to give Schwan credit for R&D vision, but I still see Genentech losing more than Roche gains. Report | Follow John on Twitter

> Scottish biotech company Sistemic Ltd today announced that it had closed a $1 million Series A round with lead investors ChimeraBio and the Scottish Enterprise Scottish Co-Investment Fund. The company will use the funding to further develop its SistemRNA compound-centric drug discovery technology. Release

> Keryx Pharmaceuticals and the FDA have agreed on a trial design for a late-stage study of its cancer drug perifosine. Report

> AMAG Pharmaceuticals shares slid this morning after an analyst downgraded the company's stock citing concerns that patients on Feraheme--an iron replacement therapy--are landing in the hospital with severe allergic reactions. Story

> The Belgian chemicals company Taminco has cancelled its planned IPO, citing a poor market for new offerings. Report

Pharma News

  @FiercePharmaGlobes (Israel): Supreme Court bars Sun from buying more Taro shares. Article | Follow @FiercePharma 

> The pace of biopharma dealmaking has increased so much that the U.S. Federal Trade Commission is asking for more funding to help handle the workload. Story

> Former Novartis CEO Dan Vasella's 2009 bonus will be close to three times the amount he would be due based on relative earnings growth among large-cap peers, according to a new corporate-governance report. Story

> Two pieces of news on federal healthcare spending today could give a forward-looking pharma executive pause. Item

> Here's another cost-cutting move at a drugmaker that managed to grow sales in 2009 but expects big competition once a major drug hits the patent cliff. Report

> Over the last week or so, we've seen three Big Pharmas announce big changes to their research operations--and those big changes include big job cuts. Big cost savings, too, the companies say. Story

Pharma Manufacturing News

> Some creative thinking in the business development group has positioned a maker of modernized traditional Chinese medicine for entry into the traditional medicinal liquor business. Report

> Airlines are showing a kinder face to drugmakers than they have been to consumers recently. Cold chain initiatives are underway at major air carriers, thanks to the growing global market for pharmaceuticals. Story

> The FDA's 2011 budget request, as reported earlier, includes $25 million for a 50-person regulatory science initiative to help the watchdog catch up with industry capabilities in the life sciences. Nanotechnology is a prime target for expertise development, according to the budget request, as is stem cell technology. Item

> While the FDA studies up on nanotechnology and stem cells, assuming its 2011 budget request is approved (see related story), the regulator will simultaneously update its drug review processes. Report

> Better means of sharing cargo theft information came online this week. Freight carriers, shippers, insurers and law enforcement are collaborating on maintaining a database and secure network to help law enforcement react faster when thefts occur. Story

> Pall Corp has unveiled the PallSep Biotech system for separating target molecules from process fluids via vibrating membrane filtration technology. Report

Vaccines News

> Twelve years ago, Dr. Andrew Wakefield published a study in the Lancet that linked autism with childhood vaccines, triggering an explosive controversy that continues to influence public opinion about the potential side effects of vaccines. Story

> An experimental malaria vaccine originally developed by GlaxoSmithKline and the U.S. Army has produced dramatic results in an early-stage trial in Mali. Story

> The nonprofit group PATH is seeking help from the FDA to develop a vaccine against diseases caused by the Streptococcus pneumoniae bacteria, which kills almost 1 million children each year. Report

> Paul Bogorad at Putnam Associates is bullish about the vaccine business. Report

And Finally... After lying in what doctors termed a vegetative state for five years, researchers in Belgium say that their patient is exhibiting brain activity that indicates a direct ‘yes' or ‘no' response to specific questions. And the discovery opens an avenue of communication even as it also raises serious new ethical considerations. Article

Suggested Articles

Cedrik Britten, M.D., becomes the biotech’s new chief medical officer to help run its adoptive cell therapy and TCR bispecifics platform.

Five Prime Therapeutics’ clinical development lead is hoping for a more stable time at new employer Spectrum Pharma.

The update comes as Gilead closes in on a FDA approval that will position it to compete with JAK inhibitors sold by AbbVie, Eli Lilly and Pfizer.